Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 1
Locations
Japan
Study Type
Interventional
Intervention
GSK716155 for injection
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring GLP-1, type 2 diabeted mellitus, safety, GSK716155, GLP-1 receptor agonist, tolerability, pharmacokinetics, pharmacodynamics
Eligibility Criteria
Inclusion criteria:
- Type 2 diabetes mellitus diagnosed at least 3 months with FPG level <=240mg/dL and HbA1c between 6.5% and 10% inclusive.
- Must be diet controlled - OR - taking a single oral antidiabetic agent (other than thiazolidinediones) and willing to withdraw from this treatment from 2 weeks prior to the study.
- Must have a BMI:<=35kg/m2, 20 to 70 years of age inclusive.
- Woman must be of non-childbearing potential.
Exclusion criteria:
- Positive test result for either syphilis, HBs antigen, HCV antibody, HIV antigen/antibody, or HTLV-1 antibody.
- Clinically significant hepatic enzyme elevation.
- History of metabolic disease other than T2DM.
- Previous use of insulin as a treatment for diabetes within 3 months.
- History of severe gastrointestinal disease.
- Clinically significant cardiovascular disease.
- Significant renal disease as defined by screening lab test.
- History of drug (including albumin or albumin containing agents) allergy.
- History of alcohol or drug abuse.
- Donation of blood in excess of 400mL within previous 4 months.
- Previously received any GLP-1 mimetic or any other albumin-containing products.
Sites / Locations
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Subjects receiving GSK716155 + placebo
Arm Description
Eligible subjects will receive GSK716155 with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks. Subjects will also receive placebo.
Outcomes
Primary Outcome Measures
Plasma concentrations and PD parameters over time and at the end of study
Secondary Outcome Measures
Other metabolic parameters at the end of study
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00530309
Brief Title
Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus
Official Title
Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus -A Phase I/II Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of GSK716155 in Japanese Subjects With Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
August 1, 2007 (Actual)
Primary Completion Date
April 17, 2008 (Actual)
Study Completion Date
April 17, 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
A Phase I/II study to investigate the safety, pharmacokinetics and pharmacodynamics of GSK716155 in Japanese subjects with type 2 diabetes mellitus
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
GLP-1, type 2 diabeted mellitus, safety, GSK716155, GLP-1 receptor agonist, tolerability, pharmacokinetics, pharmacodynamics
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Subjects receiving GSK716155 + placebo
Arm Type
Experimental
Arm Description
Eligible subjects will receive GSK716155 with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks. Subjects will also receive placebo.
Intervention Type
Drug
Intervention Name(s)
GSK716155 for injection
Intervention Description
GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Subjects will also receive placebo.
Primary Outcome Measure Information:
Title
Plasma concentrations and PD parameters over time and at the end of study
Time Frame
Up to Week 9
Secondary Outcome Measure Information:
Title
Other metabolic parameters at the end of study
Time Frame
Up to Week 9
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Type 2 diabetes mellitus diagnosed at least 3 months with FPG level <=240mg/dL and HbA1c between 6.5% and 10% inclusive.
Must be diet controlled - OR - taking a single oral antidiabetic agent (other than thiazolidinediones) and willing to withdraw from this treatment from 2 weeks prior to the study.
Must have a BMI:<=35kg/m2, 20 to 70 years of age inclusive.
Woman must be of non-childbearing potential.
Exclusion criteria:
Positive test result for either syphilis, HBs antigen, HCV antibody, HIV antigen/antibody, or HTLV-1 antibody.
Clinically significant hepatic enzyme elevation.
History of metabolic disease other than T2DM.
Previous use of insulin as a treatment for diabetes within 3 months.
History of severe gastrointestinal disease.
Clinically significant cardiovascular disease.
Significant renal disease as defined by screening lab test.
History of drug (including albumin or albumin containing agents) allergy.
History of alcohol or drug abuse.
Donation of blood in excess of 400mL within previous 4 months.
Previously received any GLP-1 mimetic or any other albumin-containing products.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Fukuoka
ZIP/Postal Code
812-0025
Country
Japan
Facility Name
GSK Investigational Site
City
Tokyo
ZIP/Postal Code
130-0004
Country
Japan
Facility Name
GSK Investigational Site
City
Tokyo
ZIP/Postal Code
160-0017
Country
Japan
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Citations:
PubMed Identifier
19863477
Citation
Seino Y, Nakajima H, Miyahara H, Kurita T, Bush MA, Yang F, Stewart MW. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin. 2009 Dec;25(12):3049-57. doi: 10.1185/03007990903372999.
Results Reference
background
PubMed Identifier
25387217
Citation
Young MA, Wald JA, Matthews JE, Scott R, Hodge RJ, Zhi H, Reinhardt RR. Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. Postgrad Med. 2014 Nov;126(7):84-97. doi: 10.3810/pgm.2014.11.2836.
Results Reference
derived
Links:
URL
https://www.clinicalstudydatarequest.com
Description
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Available IPD and Supporting Information:
Available IPD/Information Type
Study Protocol
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
GLP107865
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Clinical Study Report
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
GLP107865
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Individual Participant Data Set
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
GLP107865
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Statistical Analysis Plan
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
GLP107865
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Dataset Specification
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
GLP107865
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Informed Consent Form
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
GLP107865
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Annotated Case Report Form
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
GLP107865
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Learn more about this trial
Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs